AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 12 min read$TEVA

Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar

Teva Pharmaceutical (TEVA) and Samsung Bioepis agreed to develop and commercialize up to six biosimilar candidates, including SB41 and SB44. Teva will handle sales in key markets, while Samsung Bioepis leads development. TEVA is trading at $39.60, deemed 137.8% overvalued by GF Value™, with a GF Score™ of 60. Insiders sold $14.6M in shares over the past year.

Original reporting
gurufocus.com
Published Oct 1, 2026, 9:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TEVA
Bullish
medium confidence
Mentioned
$TEVA
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The collaboration could accelerate Teva's entry into high‑growth biosimilar markets, but financial constraints may limit execution.

02

Market read

First‑report partnership adds pipeline depth for Teva, potentially influencing biosimilar sector sentiment.

03

What to watch

Insider sales and modest financial strength could signal internal concerns despite the deal.

Relevance 7/10Novelty 7/10Timing: today

Background

Teva is a large generic and biosimilar manufacturer; Samsung Bioepis is a leading Korean biosimilar developer.

Company-level read

Ticker impact

$TEVABullishMedium confidence
Context

Teva announced a global partnership with Samsung Bioepis to develop and commercialize up to six biosimilar candidates.

Expected impact

potential upside as investors price in the expanded biosimilar portfolio

Evidence & confidence

Partnership adds pipeline depth; however, current overvaluation and weak financial strength temper the upside.

Market effects

Sector

Strengthens the biosimilars segment and may pressure peers to seek similar collaborations.

Regional

U.S., Europe and Canada markets could see modest activity in generic and biosimilar stocks.

Global

Highlights growing collaboration between U.S. and Asian biotech firms.

Counterpoint

What could challenge this read

Teva's high valuation and weak balance sheet may limit the partnership's upside.

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd

    U.S.-listed generic drug maker.

  • Company
    Samsung Bioepis Co., Ltd

    Korean biosimilar developer.

Read at source← All news

Related articles

OCT 1
$TEVAHigh

TD Cowen initiates Teva Pharma stock with buy rating on pipeline

TD Cowen initiated coverage on Teva Pharmaceutical (TEVA) with a buy rating and $55 price target, citing its pipeline and growth prospects. TEVA is near its 52-week high and has returned 98% over the past year. The FDA accepted Teva's NDA for ecopipam, and Moody's upgraded the company to investment grade. Other analysts also see growth potential in Teva's products.

investing.com2 min
SEP 30
$TEVALow

Teva Pharmaceutical Names Serge Rogasik CEO of TAPI Division, Ti

Teva Pharmaceutical (TEVA) appointed Serge Rogasik as CEO of its Technology & API Services division. The company's stock is trading at $39.60, 137.8% above its GF Value™ of $16.65, indicating significant overvaluation. TEVA has a GF Score™ of 60, with strengths in profitability and momentum but weaknesses in financial strength, growth, and valuation. Insiders have sold $14.6 million in shares over the past year with no insider buying.

gurufocus.com2 min
SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min